Secondary outcomes include neutrophil migratory capacity ; reactive oxygen species production ; neutrophil phagocytic capacity ; safety and tolerability of simvastatin administration within this patient group ; biological markers of neutrophil activation , the inflammatory response , alveolar epithelial and endothelial injury ; systemic endothelial function biomarkers and pulmonary extracellular matrix degradation .